AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
216.26
-1.35 (-0.62%)
At close: Sep 16, 2025, 4:00 PM EDT
216.14
-0.12 (-0.06%)
After-hours: Sep 16, 2025, 7:53 PM EDT
AbbVie Revenue
AbbVie had revenue of $15.42B in the quarter ending June 30, 2025, with 6.65% growth. This brings the company's revenue in the last twelve months to $58.33B, up 6.05% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$58.33B
Revenue Growth
+6.05%
P/S Ratio
6.56
Revenue / Employee
$1,060,509
Employees
55,000
Market Cap
382.04B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
Thermo Fisher Scientific | 43.21B |
ABBV News
- 4 days ago - AbbVie Stock Hit a Record on ‘Big Win' for Blockbuster Drug. The Case for Buying In. - Barrons
- 5 days ago - AbbVie shares hit record high as key immunology drug set for exclusivity until 2037 - Reuters
- 5 days ago - AbbVie in Settlement With Generic Drugmakers on Rinvoq - WSJ
- 5 days ago - Why Is AbbVie Stock Trading Higher On Thursday? - Benzinga
- 5 days ago - AbbVie: What's Happening With ABBV Stock? - Forbes
- 6 days ago - US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says - Reuters
- 7 days ago - AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 7 days ago - BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories - PRNewsWire